BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGuangzhou, China/ Hyderabad, India – March 26,2025 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosimilars, and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr.Reddy’s Laboratories...
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
Bio-TheraSolutions, a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars hassigned an exclusive License and Commercialisation Agreement with WorldMedicine , Türkiye'spharmaceutical export champion, continuingits mission of providing accessible an...
